DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
10 Maio 2023 - 9:00AM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced that its board of directors
(“the board”) has granted an equity award to its new chief
executive officer, Bret Christensen. The award was granted pursuant
to the terms of Mr. Christensen’s employment letter and as a
material inducement to his joining DermTech as president, CEO and a
director on its board.
On May 6, 2023, the board approved, subject to the commencement
of Mr. Christensen’s employment on May 8, 2023, the grant of an
option to purchase up to 500,000 shares of the Company’s common
stock pursuant to the Company’s Second Amended and Restated 2022
Inducement Equity Incentive Plan as an inducement material to Mr.
Christensen entering into employment with the Company in accordance
with NASDAQ Listing Rule 5635(c)(4). The stock option has an
exercise price of $2.49 per share and a 10-year term. Subject to
Mr. Christensen’s continued employment, twelve thirty-sixths
(12/36) of the shares of the Company’s common stock exercisable
pursuant to the option will vest on the first anniversary of the
date of grant and the remaining twenty-four thirty-sixths (24/36)
will vest in a series of eight (8) equal quarterly installments on
the fifth day of each third month thereafter.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “positioned,” “budget,”
“forecast,” “opportunity,” "outlook," “anticipate,” “future,”
“intend,” “plan,” “may,” “will,” “could,” “vision,” “should,”
“believe,” “predict,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, and DermTech’s positioning
and potential growth, financial outlook and future financial
performance. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results. Most of these factors
are outside of the control of DermTech and are difficult to
predict. Factors that may cause such differences include, but are
not limited to: (1) the outcome of any legal proceedings that may
be instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare, government payers and commercial payers; (5) the ability
of patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees and
maintain or improve its operating efficiency and reduce operating
expenses; (7) changes in applicable laws or regulations; (8) the
market adoption and demand for DermTech’s products and services
together with the possibility that DermTech may be adversely
affected by other economic, business, and/or competitive factors;
and (9) other risks and uncertainties included in the “Risk
Factors” section of the most recent Annual Report on Form 10-K
filed by DermTech with the Securities and Exchange Commission (the
“SEC”), and other documents filed or to be filed by DermTech with
the SEC, including subsequently filed reports. DermTech cautions
that the foregoing list of factors is not exclusive. You should not
place undue reliance upon any forward- looking statements, which
speak only as of the date made. DermTech does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230510005335/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024